Trials / Recruiting
RecruitingNCT05690581
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
A Nonrandomized, Open-label, Multicenter, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects with Advanced Solid Tumors and Hematologic Malignancies
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 146 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic Malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CM369 | Specified dose on specified days. |
Timeline
- Start date
- 2023-02-23
- Primary completion
- 2025-10-30
- Completion
- 2026-02-28
- First posted
- 2023-01-19
- Last updated
- 2024-12-27
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05690581. Inclusion in this directory is not an endorsement.